Combined cetuximab and volumetric modulated arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp

Dermatology Reports

Volumn 3, Issue 3, 2011, Pages

  Wollina, Uwe ^a   Schreiber, Andreas ^a   Merla, Knut ^a   Haroske, Gunter ^a  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

Advanced squamous cell carcinoma; Cetuximab; Volumetric modulated arc therapy

Indexed keywords

CETUXIMAB; DIMETINDENE; ONDANSETRON; PREDNISOLONE; RANITIDINE;

ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CARCINOMATOSIS; CASE REPORT; CHILL; CLINICAL EFFECTIVENESS; COMORBIDITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERURICEMIA; LIVER CIRRHOSIS; LOADING DRUG DOSE; LYMPHANGIOMA; MALE; MUSCLE HYPERTONIA; RECURRENT CANCER; ROSACEA; SCALP TUMOR; SKIN METASTASIS; SKIN ULCER; SQUAMOUS CELL CARCINOMA; THERAPY EFFECT; TREATMENT DURATION;

EID: 84859611059     PISSN: 20367392     EISSN: 20367406     Source Type: Journal    
DOI: 10.4081/dr.2011.e57     Document Type: Article

References (41)

1. Schmitt J, Seidler A, Diepgen TL, Bauer A. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 2011;164:291-307.
2. Stang A, Ziegler S, Büchner U, et al. Malignant melanoma and nonmelanoma skin cancers in Northrhine-Westphalia, Germany: a patient- vs. diagnosis-based incidence approach. Int J Dermatol 2007; 46:564-570.
3. Brewster DH, Bhatti LH, Inglis JH, et al. Recent trends in incidence of nonmelanoma skin cancer in the East of Scotland, 1992-2003. Br J Dermatol 2007; 156:1295-300.
4. Revenga Arranz F, Paricio Rubio JF, Mar Vásquez Salvado M, del Villar Sordo V. Decriptive epidemiology of basal cell carcinoma and cutaneous squamous cell carcinoma in Soria (north-east Spain) 1998-2000: a hospital-based survey. J Eur Acad Dermatol Venereol 2004;18:137-41.
5. Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol 2011;64:1051-9.
6. Ho T, Byrne PJ. Evaluation and initial management of the patient with facial skin cancer. Facial Plast Surg Clin North Am 2009;17:301-7.
7. Jambusaria-Pahlajani A, Miller CJ, Quon H, et al. Surgical monotherapy versus surgery plus adjuvant radiotherapy in highrisk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg 2009;35:574-85.
8. Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 2010;15:1320-8.
9. Wollina U, Hansel G, Koch A, Köstler E. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol 2005;131:300-4.
10. Jirakulaporn T, Endrizzi B, Lindgren B, et al. Capecitabine for skin cancer prevention in solid organ-transplanted recipients. Clin Transplant 2010;doi:10.1111/j. 1399-0012.2010.01348.x.
11. Wollina U, Prochnau D, Hoffmann A, et al. Vasoactive intestinal peptide and epidermal growth factor: co-mitogens or inhibitors of keratinocyte proliferation in vitro? Int J Mol Med 1998;2:725-30.
12. Maubec E, Duvillard P, Velasco V, et al. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 2005;25:1205-10.
13. Schlauder SM, Calder KB, MoodyP, Morgan MP. HER2 and EGFR expression in cutaneous spindle squamous cell carcinoma. Am J Dermatopathol 2007;29:559-63.
14. Toll A, Salgado R, Yèbenes M, et al. Epidermal growth factor receptor gene numerical aberrations are frequent in actinic keratoses and invasive cutaneous squamous cell carcinoma. Exp Dermatol 2010;19:151-3.
15. Amini S, Viera MH, Valins W, Berman B. Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthetic Dermatol 2010;3:20-34.
16. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-8.
17. Humbert Y. Cetuximab: an IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother 2004; 5:1621-33.
18. Specenier P, Vermorken JB. Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 2011;11:511-4.
19. Harrington KJ, Kazi R, Bhide SA, et al. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents. Indian J Cancer 2010;47:248-59.
20. Tejani MA, Cohen RB, Mehra R. The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics Targets Therapy 2010;4:173-85.
21. Dequanter D, Shala M, Paulus P, Lothaire P. Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials. Cancer Management Res 2010;2:165-8.
22. Ho C. Cetuximab in locally advanced headand-neck cancer: defining the population. Curr Oncol 2010;17:48-51.
23. Kim S, Eleff M, Nicolaou N. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck 2011;33:286-8.
24. Miller K, Sherman W, Ratner D. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg 2010;36:2069-74.
25. Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 2007;143:889-92.
26. Arnold AW, Bruckner-Tuderman I, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patients with severe recessive dystrophic epidermolysis bullosa. Dermatology 2009;219:80-3.
27. Giacchero D, Barrière J, Benezery K, et al. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma - a report of eight cases.Clin Oncol (R Coll Radiol) 2011; 23: 716-8.
28. National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf pages 73-74.
29. Skinner M. 2010. Available at: http://my.varian.com/files/Varian%20AAPM %20Users%20Meeting%202010%20-%20Skinner.pdf.
30. Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008;9:713-20.
31. Jennings L, Schmults CD. Management of high-risk cutaneous squamous cell carcinoma. J Clin Aesthet Dermatol 2010;3:39-48.
32. Maubec E, Petrow P, Duvillard P, et al. Cetuximab as first-line monotherapy in patients with unresectable squamous cell carcinoma: final results of a phase II mutlicenter study [abstract]. J Clin Oncol 2010;28:8510.
33. Kotoula V, Lambaki S, Televantou D, et al. STAT-related profiles are associated with patient response to targeted treatments in locally advanced SCCHN. Translation Oncol 2011;4:47-58.
34. Galer CE, Corey CL, Wang Z, et al. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck 2011;33:189-98.
35. Pessaux P, Panaro F, Casnedi S, et al. Targeted molecular therapies (Cetuximab and bevacicumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. Eur J Surg Oncol 2010:36:575-82.
36. Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett 2007;12:1-5.
37. Giro C, Berger B, Bölke E, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 2009;90:166-71.
38. Skvortsova I. Oxidative damage and cutaneous reactions during radiotherapy in combination with cetuximab. Radiother Oncol 2009;90:281-2.
39. Wojcicka JB, Lasher DE, McAfee SS, Fortier GA. Dosimetric comparison of three different techniques in extensive scalp lesion irradiation. Radiother Oncol 2009;91:255-60.
40. Mallik S, Master Z, Gupta T, et al. Brain sparing whole skull/scalp radiotherapy: unique application of helical tomotherapy [abstract]. Int J Radiation Oncol Biol Physics 2009;75:729.
41. Agazaryan N, Tenn S, Chow P, et al. Total scalp irradiation: comparison between volumetric modulated arc therapy, helical tomotherapy and conventional electron and photon field combination. Med Physics 2010;37:3319.